This is a working overview of storage stability, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-19 and is reviewed periodically as new material appears.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The numerous added equipment and consumables for the day-long mission boosted the weight of Faith 7 considerably; it now weighed over 3,000 pounds (1,400 kg). On March 15, the Atlas was rolled out of the factory a second time and passed tests with flying colors; Convair engineers expressed confidence that this "was their best bird yet." The booster actuators were offset slightly to prevent a recurrence of the liftoff roll transient that occurred on Mercury-Atlas 8. Several minor modifications were made to 130D as a result of postflight findings from failed Atlas launches over the previous year. These included adding a plastic liner to the inside of the turbopumps to prevent the turbine blades from rubbing against the casing and triggering an explosion from a friction spark, improvements to the wiring of the programmer, and additional steps taken to prevent the possibility of a fire breaking out in or around the thrust section. The upgraded MA-2 engines featured baffled injector heads and a hypergolic igniter, eliminating any concerns of rough combustion or the need for hold-down time prior to liftoff. As such, the RCC (Rough Combustion Cutoff) sensors on 130D were operated open loop and for qualitative purposes only. The propellant conserved by not performing the three second hold-down time would allow a longer booster burn. On Mercury-Atlas 8, 112 gallons of fuel were removed prior to launch and so an extended burn was not possible even with eliminating the hold-down, but on this flight there would be enough propellant to extend burn time.
Tazarotene, sold under the brand name Tazorac, among others, is a third-generation prescription topical retinoid. It is primarily used for the treatment of plaque psoriasis and acne. Tazarotene is also used as a therapeutic for photoaged and photodamaged skin. It is a member of the acetylenic class of retinoids. Tazarotene was approved for medical use in 1997 and is available as a generic medication.
== Career and research == In 1981, Busslinger joined the lab of Richard A. Flavell at the MRC Institute Mill Hill in London as a postdoctoral fellow. There, he discovered that a single nucleotide mutation in the first intron of the β-globin gene causes β+-thalassemia and that DNA methylation of promoter sequences prevents gene transcription. In 1983, Busslinger became a Group Leader at the Institute of Molecular Biology II of the University of Zurich. Here, he discovered a new set of histone genes of the sea urchin and identified a tissue-specific transcription factor (TSAP) as an essential regulator of these genes, which later turned out to be a member of the Paired box (Pax)-containing transcription factor family. In 1987, Max Birnstiel recruited Busslinger to join the newly founded Research Institute of Molecular Pathology (IMP) in Vienna, Austria, as one of the first Senior Scientists. In 1996, Busslinger was appointed Professor at the University of Vienna. In 2007, he became the IMP's Director of Academic Affairs and, in 2013, Scientific Deputy Director. At the IMP, Busslinger changed his research focus from sea urchin embryogenesis to B cell immunology, which was promoted by the identification of a B-cell-specific transcription factor as a mammalian homologue of the sea urchin regulator TSAP. Protein purification and sequencing identified the B-cell-specific transcription factor as Pax5, and gene inactivation in the mouse defined Pax5 an essential regulator of B cell development.
Sources: en.wikipedia.org
The CDC Good laboratory practice guidelines for newborn screening recommend that "laboratory specimen retention procedures should be consistent with patient decisions." Researchers have described the NBS samples as a gold mine representing a patient population that would otherwise be impossible to get. The American Civil Liberties Union (ACLU), Council for Responsible Genetics(CRG), and the International Association of Privacy Professionals(IAPP) oppose the long term storage of identifiable NBS blood spots. In 2009, the Texas NBS program had to destroy millions of stored blood spots that had been stored for decades without consent. In Michigan, a 2022 lawsuit found that the NBS program long term storage and sales to third-parties was found to violate state statues noting how "post-testing conduct is not necessary to effectuate that interest because 'the health of the child is no longer at stake.'" In New Jersey, the Institute for Justice filed a class-action lawsuit in 2022 under the 4th amendment seeking to limit the retention period of NBS cards after they were found to be used in warrantless law enforcement investigations without consent.
=== On resin cyclization === Peptides can be cyclized on a solid support. A variety of cyclization reagents can be used such as HBTU/HOBt/DIEA, PyBop/DIEA, PyClock/DIEA. Head-to-tail peptides can be made on the solid support. The deprotection of the C-terminus at some suitable point allows on-resin cyclization by amide bond formation with the deprotected N-terminus. Once cyclization has taken place, the peptide is cleaved from resin by acidolysis and purified. The strategy for the solid phase synthesis of cyclic peptides is not limited to attachment through Asp, Glu or Lys side chains. Cysteine has a very reactive sulfhydryl group on its side chain. A disulfide bridge is created when a sulfur atom from one cysteine forms a single covalent bond with another sulfur atom from a second cysteine in a different part of the protein. These bridges help to stabilize proteins, especially those secreted from cells. Some researchers use modified cysteines using S-acetamidomethyl (Acm) to block the formation of the disulfide bond but preserve the cysteine and the protein's original primary structure.
The concerns about the adverse effects of non-noble varieties, produced by their undesirable composition of kavalactones and high concentrations of potentially harmful compounds (flavokavains, which are not present in any significant concentration in the noble varieties), have led to legislation prohibiting exports from countries such as Vanuatu. Likewise, efforts have been made to educate non-traditional customers about the difference between noble and non-noble varieties and that non-noble varieties do not offer the same results as noble cultivars. In recent years, government regulatory bodies and non-profit NGOs have been set up with the declared aim of monitoring kava quality; producing regular reports; certifying vendors selling proper, noble kava; and warning customers against products that may contain tudei varieties.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.